

Cytokine Release Syndrome – Pipeline Insight, 2020

<https://marketpublishers.com/r/C05E61E4F78EEN.html>

Date: October 2020

Pages: 65

Price: US\$ 1,500.00 (Single User License)

ID: C05E61E4F78EEN

Abstracts

This report can be delivered to the clients within 24 - 48 Hours

DelveInsight's, "Cytokine Release Syndrome – Pipeline Insight, 2020," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cytokine Release Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cytokine Release Syndrome Understanding

Cytokine Release Syndrome: Overview

A condition that may occur after treatment with some types of immunotherapy, such as monoclonal antibodies and CAR-T cells. Cytokine release syndrome is caused by a large, rapid release of cytokines into the blood from immune cells affected by the immunotherapy. Cytokines are immune substances that have many different actions in the body.

Symptoms

Signs and symptoms of cytokine release syndrome include fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing. Most patients have a

mild reaction, but sometimes, the reaction may be severe or life threatening.

Treatment

As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important. Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ , and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome.

Cytokine Release Syndrome Emerging Drugs Chapters

This segment of the Cytokine Release Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytokine Release Syndrome Emerging Drugs

Canakinumab: Novartis

Canakinumab is an interleukin (IL)-1 β blocker indicated to treat certain periodic fever syndromes, such as cryopyrin-associated periodic syndromes and systemic juvenile idiopathic arthritis. Novartis is conducting phase III trial, called CAN-COVID which will evaluate the drug's efficacy in treating a type of severe immune overreaction called cytokine release syndrome (CRS) related to Covid-19 pneumonia.

Itacitinib: Incyte Corporation

Itacitinib is a potent, selective JAK1 inhibitor which is being clinically evaluated in several inflammatory diseases. It is currently being evaluated in phase II stage for the prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy.

Dapansutrile: Olatec Therapeutics LLC

Dapansutrile is being developed by Olatec Therapeutics LLC for the treatment of Cytokine Release Syndrome. It is currently being evaluated in phase II trial to determine safety and efficacy of Dapansutrile for treatment of moderate COVID-19 symptoms and evidence of Early Cytokine Release Syndrome.

Further product details are provided in the report.

Cytokine Release Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Cytokine Release Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cytokine Release Syndrome

There are approx. 5+ key companies which are developing the therapies for Cytokine Release Syndrome. The companies which have their Cytokine Release Syndrome drug candidates in the most advanced stage, i.e. phase III include Novartis and others

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cytokine Release Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravenous

Oral

Parenteral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytokine Release Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytokine Release Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytokine Release Syndrome drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytokine Release Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Cytokine Release Syndrome.

In July 2020, India's medical authorities approve Biocon Biologic's itolizumab, an anti-CD6 IgG1 monoclonal antibody, for emergency treatment of cytokine release syndrome in patients with coronavirus disease 2019 (COVID-19).

Cytokine Release Syndrome Report Insights

Cytokine Release Syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cytokine Release Syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cytokine Release Syndrome drugs?

How many Cytokine Release Syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytokine Release Syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cytokine Release Syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cytokine Release Syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Biocon Limited

Olatec Therapeutics LLC

Novartis Pharmaceuticals

Key Products

Itacitinib

Dapansutrile

Canakinumab

Ruxolitinib

Contents

Introduction

Executive Summary

Cytokine Release Syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cytokine Release Syndrome – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Cytokine Release Syndrome companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Cytokine Release Syndrome Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Canakinumab: Novartis

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Itacitinib: Incyte Corporation

Product Description

Research and Development

Product Development Activities

Dapansutrile: Olatec Therapeutics LLC

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Cytokine Release Syndrome Key Companies
Cytokine Release Syndrome Key Products
Cytokine Release Syndrome- Unmet Needs
Cytokine Release Syndrome- Market Drivers and Barriers
Cytokine Release Syndrome- Future Perspectives and Conclusion
Cytokine Release Syndrome Analyst Views
Cytokine Release Syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cytokine Release Syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Cytokine Release Syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Cytokine Release Syndrome – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/C05E61E4F78EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C05E61E4F78EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970